Reversing cachexia

Michael J. Tisdale

doi:10.1016/j.cell.2010.08.004

Reversing cachexia

Michael J. Tisdale^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

Original language	English
Pages (from-to)	511-512
Number of pages	2
Journal	Cell
Volume	142
Issue number	4
DOIs	https://doi.org/10.1016/j.cell.2010.08.004
Publication status	Published - 20 Aug 2010

Access to Document

10.1016/j.cell.2010.08.004

https://www.sciencedirect.com/science/article/pii/S0092867410008998?via%3DihubLicence: Other

Cite this

@article{02e67cc7dbd34a33b215a9d6f4d00249,

title = "Reversing cachexia",

abstract = "Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.",

author = "Tisdale, {Michael J.}",

year = "2010",

month = aug,

day = "20",

doi = "10.1016/j.cell.2010.08.004",

language = "English",

volume = "142",

pages = "511--512",

journal = "Cell",

issn = "0092-8674",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Reversing cachexia

AU - Tisdale, Michael J.

PY - 2010/8/20

Y1 - 2010/8/20

N2 - Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

AB - Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

UR - http://www.scopus.com/inward/record.url?scp=77955702860&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2010.08.004

DO - 10.1016/j.cell.2010.08.004

M3 - Article

AN - SCOPUS:77955702860

SN - 0092-8674

VL - 142

SP - 511

EP - 512

JO - Cell

JF - Cell

IS - 4

ER -

Reversing cachexia

Abstract

Access to Document

Other files and links

Fingerprint

Cite this